Copyright © 2021. Inderes Oyj. All rights reserved.

Optomed

Analyst

Juha Kinnunen

Juha Kinnunen

Osakestrategi, analyytikko

Read more

Latest insider trading

Net impact profile

Third party research
6.5.
2022

Redeye maintains its valuation of Optomed after the Q1 report.

Third party research
18.2.
2022

Redeye maintains its positive view and valuation of Optomed. The company refocuses its sales efforts from the Eastern markets to the USA and Western Europe.

Third party research
8.2.
2022

Redeye believes there is a high likelihood Optomed will receive an approval by the FDA for the marketing of the autonomous AI for more than mild diabetic retinopathy - based on the presented clinical trial results with Aurora AEYE.

Third party research
14.7.
2021

Redeye revises slightly its revenue and EBITDA projections for 2021. While we remain conservative in our near-term expectations, we maintain our conviction that Optomed is on the path of spectacular growth.

Third party research
11.5.
2021

Redeye sees one more sign for sales growth for Optomed with the market authorization for the Aurora camera in Brazil.

Third party research
6.5.
2021

Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.

Third party research
12.4.
2021

Redeye raises the fair value of Optomed to EUR 13 per share, a new bull case of EUR 17 per share and a bear case of EUR 5. As we expected, the trend for "remote-everything" favours Optomed. We believe this transformation will continue and even accelerate in the coming years and see Optomed as positioned for strong growth with both superior technology and solid execution capability.

Optomed

Eesti keel translation unavailable for Optomed.